Açıklama

Quality assessment of included clinical trials evaluating probiotics for IBS treatment. Risk of bias across randomization, blinding, and outcome reporting domains is summarized for each study.

Figure 7

Chart

Source Paper

Evaluating the Efficacy of Probiotics in IBS Treatment Using a Systematic Review of Clinical Trials and Multi-Criteria Decision Analysis.

Nutrients (2022)

PMID: 35807868

DOI: 10.3390/nu14132689

Cite This Figure

![Figure 7: Quality assessment of included clinical trials evaluating probiotics for IBS treatment. Risk of bias across randomization, blinding, and outcome reporting domains is summarized for each study.]()

> Source: Cecilia Ceccherini et al. "Evaluating the Efficacy of Probiotics in IBS Treatment Using a Systematic Review." *Nutrients*, 2022. PMID: [35807868](https://pubmed.ncbi.nlm.nih.gov/35807868/)

<figure>
  <img src="" alt="Quality assessment of included clinical trials evaluating probiotics for IBS treatment. Risk of bias across randomization, blinding, and outcome reporting domains is summarized for each study." />
  <figcaption>Figure 7. Quality assessment of included clinical trials evaluating probiotics for IBS treatment. Risk of bias across randomization, blinding, and outcome reporting domains is summarized for each study.<br>  Source: Cecilia Ceccherini et al. "Evaluating the Efficacy of Probiotics in IBS Treatment Using a Systematic Review." <em>Nutrients</em>, 2022. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35807868/">35807868</a></figcaption>
</figure>

İlgili Kanıtlar

Lactobacillus acidophilus için Irritable Bowel Syndrome (IBS)

Derece B · 3 çalışma